Open Access Research
Response surface optimization and in vitro study of nasal solusomes nanovesicles for the bioavailability improvement and brain targetting of sumatriptan
Ahmed H Salman1,*
, Hussein K. Alkufi2, Salam Shanta Taher3, Sumayah Al-Mahmood4, Mahmood A. Haiss3
1Department of Pharmaceutics, College of Pharmacy, Al-bayan university, Iraq
2Department of Pharmacognosy, College of Pharmacy, University of Thi-Qar, Iraq
3Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Iraq
4Department of Basic Sciences, College of Dentistry, Al-Iraqia University, Iraq
*Corresponding author
Hussein K. Alkufi, Department of pharmacognosy, College of Pharmacy, University of Thi-Qar, Iraq; Tel.: +9647830905105; e-mail:
husseinalkufi21@utq.edu.iq
Download PDF
Published: 27 December 2024; https://doi.org/10.61873/RNYL6796
Abstract
Background: One effective second-generation triptan for migraine attacks is sumatriptan. Following oral use, it has a 40% restricted bioavailability because of the first-pass metabolism. Aim: To develop the best intranasal Solusomes formula as a substitute that delivers into the brain directly, improving its bioavailability, and removing the first-pass outcome was the aim of this effort. Methodology: We developed solute formulations based on the Box-Behnken design and subsequently produced them via thin-film hydration. The quality by design technique was used to establish a correlation between the formulation parameters (Soluplus® and phosphatidylcholine (PC) concentrations) and significant quality powers (entrapment efficiency (EE%), vesicle size (VS), and polydispersity index (PDI)). Fourier transform infrared spectroscopy (FTIR), optical microscopy, and an in vitro diffusion study were performed on the revised formula. Results: The enhanced formulation exhibited a VS of 93.76 nm, an EE% of 83.65%, and PDI 0.3362 with the least amount of error between the projected and observed values. Conclusion: This study offered a feasible and efficient intranasal formulation appropriate for further brain delivery research.
Keywords: sumatriptan succinate, nasal bioavailability, pharmacokinetics, Soluplus®, solusomes
Please cite as:
Salman A. H., Alkufi H. K., Taher S. S., Al-mahmood S., Haiss M. A.: Response surface optimization and in vitro study of nasal solusomes nanovesicles for the bioavailability improvement and brain targetting of sumatriptan. Epitheorese Klin. Farmakol. Farmakokinet. 42(Sup1): 107-117 (2024). DOI: 10.61873/RNYL6796
pISSN 1011-6575 • eISSN 2945-1914